Literature DB >> 33735874

Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer.

Marisa J L Aitken1,2, Christopher B Benton1,3, Ghayas C Issa1, Koji Sasaki1, Musa Yilmaz1, Nicholas J Short4.   

Abstract

CML is defined by the presence of an oncogenic fusion protein caused by a reciprocal translocation between chromosomes 9q and 22q. While our molecular understanding of CML pathogenesis has revolutionized drug development for this disease, we have yet to identify many predisposing factors for CML. Familial occurrence of CML has been rarely reported. Here, we describe 2 cases of CML in a 24-year-old woman and in her 73-year-old maternal great aunt. We describe genetic variants in these patients and report on their environmental exposures that may have contributed to CML pathogenesis. The possible familial association of these 2 cases of CML warrants further investigation into more definitive etiologies of this disease.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Chronic myeloid leukemia; Familial cancer; Hereditary cancer syndromes

Mesh:

Year:  2021        PMID: 33735874      PMCID: PMC8448803          DOI: 10.1159/000513925

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  37 in total

1.  DDT/DDE and breast cancer: a meta-analysis.

Authors:  Susan Z Ingber; Melanie C Buser; Hana R Pohl; Henry G Abadin; H Edward Murray; Franco Scinicariello
Journal:  Regul Toxicol Pharmacol       Date:  2013-09-08       Impact factor: 3.271

2.  Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Authors:  Gabriel Etienne; Joëlle Guilhot; Delphine Rea; Françoise Rigal-Huguet; Franck Nicolini; Aude Charbonnier; Agnès Guerci-Bresler; Laurence Legros; Bruno Varet; Martine Gardembas; Viviane Dubruille; Michel Tulliez; Marie-Pierre Noel; Jean-Christophe Ianotto; Bruno Villemagne; Martin Carré; François Guilhot; Philippe Rousselot; François-Xavier Mahon
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

3.  Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.

Authors:  Ghayas C Issa; Hagop M Kantarjian; Graciela Nogueras Gonzalez; Gautam Borthakur; Guilin Tang; William Wierda; Koji Sasaki; Nicholas J Short; Farhad Ravandi; Tapan Kadia; Keyur Patel; Raja Luthra; Alessandra Ferrajoli; Guillermo Garcia-Manero; Mary Beth Rios; Sara Dellasala; Elias Jabbour; Jorge E Cortes
Journal:  Blood       Date:  2017-08-23       Impact factor: 22.113

4.  [Familial chronic myelogenous leukemia. Report of 3 cases in a family].

Authors:  A Avilés; A Sinco; N Zapata; R Ambriz; J Pizzuto
Journal:  Sangre (Barc)       Date:  1982

5.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

Review 6.  Inheritance of the chronic myeloproliferative neoplasms. A systematic review.

Authors:  A Ranjan; E Penninga; A M Jelsig; H C Hasselbalch; O W Bjerrum
Journal:  Clin Genet       Date:  2012-11-20       Impact factor: 4.438

7.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

Authors:  Ola Landgren; Lynn R Goldin; Sigurdur Y Kristinsson; Elin A Helgadottir; Jan Samuelsson; Magnus Björkholm
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

8.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Authors:  David M Ross; Susan Branford; John F Seymour; Anthony P Schwarer; Christopher Arthur; David T Yeung; Phuong Dang; Jarrad M Goyne; Cassandra Slader; Robin J Filshie; Anthony K Mills; Junia V Melo; Deborah L White; Andrew P Grigg; Timothy P Hughes
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

9.  Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia.

Authors:  C R Bartram; A de Klein; A Hagemeijer; T van Agthoven; A Geurts van Kessel; D Bootsma; G Grosveld; M A Ferguson-Smith; T Davies; M Stone
Journal:  Nature       Date:  1983 Nov 17-23       Impact factor: 49.962

10.  Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

Authors:  Delphine Rea; Franck E Nicolini; Michel Tulliez; François Guilhot; Joelle Guilhot; Agnès Guerci-Bresler; Martine Gardembas; Valérie Coiteux; Gaelle Guillerm; Laurence Legros; Gabriel Etienne; Jean-Michel Pignon; Bruno Villemagne; Martine Escoffre-Barbe; Jean-Christophe Ianotto; Aude Charbonnier; Hyacinthe Johnson-Ansah; Marie-Pierre Noel; Philippe Rousselot; François-Xavier Mahon
Journal:  Blood       Date:  2016-12-08       Impact factor: 22.113

View more
  2 in total

Review 1.  Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

Authors:  Yoshihiro Umezawa; Koji Sasaki
Journal:  Int J Hematol       Date:  2022-09-10       Impact factor: 2.319

Review 2.  Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects.

Authors:  Jayastu Senapati; Koji Sasaki
Journal:  Cancers (Basel)       Date:  2022-05-21       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.